Answer
Verdict
Strong consensus for
ApoB particles entering the artery wall cause heart disease.
4 sources: 3 positive, 1 partly
By Arun AgrahriLast reviewed
Short answer
Both, on the record, and this is one of its sharpest disagreements. One case holds that high cholesterol is downstream of insulin resistance, so a statin treats the number and misses the cause. The other holds that ApoB, the count of cholesterol-carrying particles, is causal, because the particle has to enter the artery wall for plaque to form. Both sides want you to measure ApoB.
positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.
ApoB particles entering the artery wall cause heart disease.
4 sources: 3 positive, 1 partly.
Researchers say
3 positive, 1 partly
Dr. Peter Attia, 6 mentions on this claim
Positive Video
on Huberman Lab, at 2:14:47 · positive
“I care about the causative agent of atherosclerosis. ApoB is the thing that drives atherosclerosis.”
on Huberman Lab, at 2:14:50 · positive
“ApoB is the thing that drives atherosclerosis.”
on FoundMyFitness, at 25:45 · positive
“a causal driver of asbd in the case of apob”
on The Drive, at 14:20 · positive
“Apo particles are the approximate driver of the of the atheroma. Um, and therefore, every LDL particle is a potential seed”
on The Drive, at 02:12 · positive
“the LDL traffics that cholesterol into the artery wall where it will get retained and oxidized and lead to the process of atherosclerosis”
on The Drive, at 11:36 · positive
“what they do is they go into artery walls where they get oxidized”
Alan Sniderman, on The Drive, at 14:22
Positive Video · Opinion
Open the tape at 14:22 →“fewer apob particles in plasma fewer get into the arterial wall fewer get trapped”
Lane Norton, on The Drive, at 1:44:12
Positive Video · Opinion
Open the tape at 1:44:12 →“the less APOB that gets retained inside the inima the less chance there is for overall oxidation to occur”
Mark Hyman, on The Dr. Hyman Show, at 1:08:58
Partly Video · Opinion
Open the tape at 1:08:58 →“it's basically this rancid fat in your blood that's the problem and inflammation”
Studies show
No study counted yet.
Dr. Peter Attia Video · positive · 6 mentions
on Huberman Lab, at 2:14:47 · positive · Opinion
“I care about the causative agent of atherosclerosis. ApoB is the thing that drives atherosclerosis.”
on Huberman Lab, at 2:14:50 · positive · Opinion
“ApoB is the thing that drives atherosclerosis.”
on FoundMyFitness, at 25:45 · positive · Opinion
“a causal driver of asbd in the case of apob”
on The Drive, at 14:20 · positive · Opinion
“Apo particles are the approximate driver of the of the atheroma. Um, and therefore, every LDL particle is a potential seed”
on The Drive, at 02:12 · positive · Opinion
“the LDL traffics that cholesterol into the artery wall where it will get retained and oxidized and lead to the process of atherosclerosis”
on The Drive, at 11:36 · positive · Opinion
“what they do is they go into artery walls where they get oxidized”
Alan Sniderman, on The Drive, at 14:22 Video · positive · Opinion
“fewer apob particles in plasma fewer get into the arterial wall fewer get trapped”
Lane Norton, on The Drive, at 1:44:12 Video · positive · Opinion
“the less APOB that gets retained inside the inima the less chance there is for overall oxidation to occur”
Mark Hyman, on The Dr. Hyman Show, at 1:08:58 Video · partly · Opinion
“it's basically this rancid fat in your blood that's the problem and inflammation”
ApoB particles entering the artery wall cause heart disease.
Dr. Peter Attia, 6 mentions on this claim
Positive Video
on Huberman Lab, at 2:14:47 · positive
“I care about the causative agent of atherosclerosis. ApoB is the thing that drives atherosclerosis.”
on Huberman Lab, at 2:14:50 · positive
“ApoB is the thing that drives atherosclerosis.”
on FoundMyFitness, at 25:45 · positive
“a causal driver of asbd in the case of apob”
on The Drive, at 14:20 · positive
“Apo particles are the approximate driver of the of the atheroma. Um, and therefore, every LDL particle is a potential seed”
on The Drive, at 02:12 · positive
“the LDL traffics that cholesterol into the artery wall where it will get retained and oxidized and lead to the process of atherosclerosis”
on The Drive, at 11:36 · positive
“what they do is they go into artery walls where they get oxidized”
Alan Sniderman, on The Drive, at 14:22
Positive Video · Opinion
Open the tape at 14:22 →“fewer apob particles in plasma fewer get into the arterial wall fewer get trapped”
Lane Norton, on The Drive, at 1:44:12
Positive Video · Opinion
Open the tape at 1:44:12 →“the less APOB that gets retained inside the inima the less chance there is for overall oxidation to occur”
Mark Hyman, on The Dr. Hyman Show, at 1:08:58
Partly Video · Opinion
Open the tape at 1:08:58 →“it's basically this rancid fat in your blood that's the problem and inflammation”
Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent
3 updates since June 2026. Each one is a dated statement on the record, timecoded to the video.
A surgeon with an ApoB of 180 who looked healthy
The most concrete entry on the record, and the one that cuts against the show's own framing. A cardiovascular surgeon who ate well and looked healthy reports his own ApoB at 180, and says a standard lipid panel would never have shown it. The inflammation-first case is being made with the measurement the other side asked for.
on the record @ 10:46Restated with a second guest, and answered again
Same argument, different clinician. Chasing LDL with statins treats the number and misses an inflammatory, insulin-driven process. Here the two sides find their one point of agreement. The number worth watching is ApoB rather than total LDL cholesterol, even while they disagree about whether it is a cause or a symptom.
on the record @ 03:05Treat the cause, not the number
The opening position. High cholesterol is mostly a downstream signal of insulin resistance and inflammation, so the move is a metabolic reset rather than a statin. The particle case answered it twice the same week, once on particle count being causal in itself and once on lifetime LDL exposure tracking linearly with mortality.
on the record @ 00:00Nobody has answered
Whether lowering ApoB in someone with no metabolic dysfunction changes outcomes. That is the exact question separating the two positions, and neither has answered it on the record. No one here has addressed the reverse either, whether fixing insulin resistance lowers ApoB enough to matter on its own.
ApoB particles entering the artery wall cause heart disease, on one reading of the record, while another reading puts inflammation first. The two positions have been argued past each other for months, and the argument matters because it changes what you would test and what you would do about the result.
Aseem Malhotra, Cindy Geyer and cardiovascular surgeon Jeremy London, each a guest on Mark Hyman's show, argue that cholesterol rises because something upstream is wrong. Insulin resistance and chronic inflammation are the disease, and the cholesterol reading is only the smoke. On that reading, prescribing a statin to lower the number treats a readout while the process underneath continues.
Peter Attia, on his own show, does not argue the mirror image. He does not call inflammation irrelevant. He argues that ApoB is mechanically required, because the particle has to cross into the artery wall for plaque to form at all.
That makes the count a cause rather than a correlation. His evidence is Mendelian randomization, a genetic method in which lifetime LDL exposure tracks linearly with mortality and genes, not lifestyle, set the exposure.
Both sides have landed on ApoB as the number to measure, over the standard lipid panel. Tom Dayspring, a guest on Attia's show, says the field standardized on ApoB because the test is consistent across labs and cheap. Ronald Krauss, a guest on Rhonda Patrick's show, calls it easy, inexpensive and widely available.
London arrives at the same place from the other side, reporting his own ApoB at 180 while looking healthy and eating well, and saying a standard panel would have missed it.
Both sides also accept that statins are over-prescribed in some groups. Krauss grants a real type-2 diabetes risk, especially in women.
No one on the record has answered whether lowering ApoB in a metabolically healthy person changes their outcome, which is the exact question the disagreement turns on. Until someone does, the practical overlap is smaller than it looks: measure ApoB, because both sides want that number, and take the interpretation to a physician rather than a podcast.
Precis membership
The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one.
A free account adds
Pro adds